268 related articles for article (PubMed ID: 28923878)
41. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
Rodríguez-Avial I; Culebras E; Betriu C; Morales G; Pena I; Picazo JJ
J Antimicrob Chemother; 2012 Jan; 67(1):167-9. PubMed ID: 21954458
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/ Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis.
Espinoza-Gonzalez NA; Welsh O; Ocampo-Candiani J; Said-Fernandez S; Lozano-Garza G; Choi SH; Vera-Cabrera L
Curr Drug Deliv; 2010 Jul; 7(3):225-9. PubMed ID: 20497102
[TBL] [Abstract][Full Text] [Related]
43. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.
Choi S; Im W; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4713-7. PubMed ID: 22713339
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial susceptibility and clinical characteristics of Nocardia isolates from a tertiary care centre diagnostic laboratory in Pakistan.
Farooqui F; Irfan S; Shakoor S; Zafar A
J Glob Antimicrob Resist; 2018 Dec; 15():219-221. PubMed ID: 30393158
[TBL] [Abstract][Full Text] [Related]
45. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017.
Huang L; Chen X; Xu H; Sun L; Li C; Guo W; Xiang L; Luo G; Cui Y; Lu B
Diagn Microbiol Infect Dis; 2019 Jun; 94(2):165-172. PubMed ID: 30679058
[TBL] [Abstract][Full Text] [Related]
46. Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis.
McTaggart LR; Doucet J; Witkowska M; Richardson SE
Antimicrob Agents Chemother; 2015 Jan; 59(1):269-75. PubMed ID: 25348540
[TBL] [Abstract][Full Text] [Related]
47. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents.
Larruskain J; Idigoras P; Marimón JM; Pérez-Trallero E
Antimicrob Agents Chemother; 2011 Jun; 55(6):2995-8. PubMed ID: 21402847
[TBL] [Abstract][Full Text] [Related]
48. Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest.
Glupczynski Y; Berhin C; Janssens M; Wauters G
Clin Microbiol Infect; 2006 Sep; 12(9):905-12. PubMed ID: 16882297
[TBL] [Abstract][Full Text] [Related]
49. Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis.
Hashemi-Shahraki A; Heidarieh P; Bostanabad SZ; Hashemzadeh M; Feizabadi MM; Schraufnagel D; Mirsaeidi M
Sci Rep; 2015 Dec; 5():17862. PubMed ID: 26638771
[TBL] [Abstract][Full Text] [Related]
50. Tedizolid for the management of human infections: in vitro characteristics.
Locke JB; Zurenko GE; Shaw KJ; Bartizal K
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S35-42. PubMed ID: 24343830
[TBL] [Abstract][Full Text] [Related]
51. Long-term use of tedizolid for pulmonary nocardiosis.
Chomei Y; Nishimura S; Iwata K
J Infect Chemother; 2022 Aug; 28(8):1172-1176. PubMed ID: 35450784
[TBL] [Abstract][Full Text] [Related]
52. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe.
Bensaci M; Sahm D
Diagn Microbiol Infect Dis; 2017 Feb; 87(2):133-138. PubMed ID: 27866673
[TBL] [Abstract][Full Text] [Related]
53. Species distribution and susceptibility of Nocardia isolates in New Zealand 2002-2021.
McKinney WP; Smith MR; Roberts SA; Morris AJ
Pathology; 2023 Aug; 55(5):680-687. PubMed ID: 37277236
[TBL] [Abstract][Full Text] [Related]
54. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
[TBL] [Abstract][Full Text] [Related]
55. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015.
Lebeaux D; Bergeron E; Berthet J; Djadi-Prat J; Mouniée D; Boiron P; Lortholary O; Rodriguez-Nava V
Clin Microbiol Infect; 2019 Apr; 25(4):489-495. PubMed ID: 29933049
[TBL] [Abstract][Full Text] [Related]
56. Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species.
Hershko Y; Levytskyi K; Rannon E; Assous MV; Ken-Dror S; Amit S; Ben-Zvi H; Sagi O; Schwartz O; Sorek N; Szwarcwort M; Barkan D; Burstein D; Adler A
J Antimicrob Chemother; 2023 Sep; 78(9):2306-2314. PubMed ID: 37527397
[TBL] [Abstract][Full Text] [Related]
57. [Comparative evaluation of e-test and disk diffusion methods for susceptibility testing of Nocardia species].
Perçin D; Sümerkan B; Inci R
Mikrobiyol Bul; 2011 Apr; 45(2):274-9. PubMed ID: 21644070
[TBL] [Abstract][Full Text] [Related]
58. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
Urbina O; Ferrández O; Espona M; Salas E; Ferrández I; Grau S
Drug Des Devel Ther; 2013; 7():243-65. PubMed ID: 23589680
[TBL] [Abstract][Full Text] [Related]
59. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
[TBL] [Abstract][Full Text] [Related]
60. In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.
González-Martínez NA; Lozano-Garza HG; Castro-Garza J; De Osio-Cortez A; Vargas-Villarreal J; Cavazos-Rocha N; Ocampo-Candiani J; Makarov V; Cole ST; Vera-Cabrera L
PLoS Negl Trop Dis; 2015; 9(10):e0004022. PubMed ID: 26474057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
